Abstract
Foscarnet was administered to eight AIDS patients for suspected cytomegalovirus (CMV) pneumonitis as a continuous intravenous infusion for a minimum of 8 days. All the patients improved, three showing complete resolution of symptoms. Evidence of CMV infection from bronchoalveolar lavage samples was lacking in two patients. Adverse drug experiences consisted of thrombophlebitis, transient decreases in haemoglobin concentration, and reversible rises in serum creatinine levels.
MeSH terms
-
Acquired Immunodeficiency Syndrome / complications*
-
Adult
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Cytomegalovirus Infections / complications
-
Cytomegalovirus Infections / drug therapy*
-
Foscarnet
-
Humans
-
Male
-
Middle Aged
-
Organophosphorus Compounds / therapeutic use*
-
Phosphonoacetic Acid / adverse effects
-
Phosphonoacetic Acid / analogs & derivatives
-
Phosphonoacetic Acid / therapeutic use*
-
Pneumonia, Viral / complications
-
Pneumonia, Viral / drug therapy*
Substances
-
Antiviral Agents
-
Organophosphorus Compounds
-
Foscarnet
-
Phosphonoacetic Acid